Cocrystal Pharma, Inc.
COCP
$1.49
-$0.06-3.87%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -53.90% | -52.26% | -22.70% | 53.80% | -24.49% |
| Gross Profit | 53.90% | 52.26% | 22.70% | -53.80% | 24.49% |
| SG&A Expenses | -18.79% | -14.72% | -2.65% | -25.88% | 0.33% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -43.70% | -42.99% | -16.56% | 25.56% | -18.65% |
| Operating Income | 43.70% | 42.99% | 16.56% | -25.56% | 18.65% |
| Income Before Tax | 41.84% | 26.84% | -18.58% | -28.25% | 23.76% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 41.84% | 26.84% | -18.58% | -28.25% | 23.76% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 41.84% | 26.84% | -18.58% | -28.25% | 23.76% |
| EBIT | 43.70% | 42.99% | 16.56% | -25.56% | 18.65% |
| EBITDA | 43.83% | 43.09% | 16.33% | -26.16% | 18.55% |
| EPS Basic | 41.82% | 26.49% | -18.36% | -26.89% | 38.98% |
| Normalized Basic EPS | 41.81% | 39.96% | 14.51% | -26.87% | 38.99% |
| EPS Diluted | 41.82% | 26.49% | -18.36% | -26.89% | 39.25% |
| Normalized Diluted EPS | 41.81% | 39.96% | 14.51% | -26.87% | 38.99% |
| Average Basic Shares Outstanding | 0.00% | -0.46% | 0.21% | 1.08% | 24.94% |
| Average Diluted Shares Outstanding | 0.00% | -0.46% | 0.21% | 1.08% | 24.94% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |